Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration

Next Previous
Trial Profile

A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adult neural stem cells (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Proof of concept; Therapeutic Use
  • Acronyms RADIANT
  • Sponsors StemCells

    • Most Recent Events

    • 31 May 2016 Status changed from suspended to discontinued based on a business decision unrelated to any safety concerns.
    • 23 Dec 2015 According to a StemCells media release, the company has decided to suspend this trial in line with a strategic realignment to fully focus the company's resources on its proprietary HuCNS-SC platform technology for the treatment of chronic spinal cord injury (SCI). The company is seeking a partner to fund continued development in retinal disorders.
    • 23 Dec 2015 Status changed from recruiting to suspended, according to a StemCells Inc., media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top